From treating depression and other mental health disorders, to helping relieve chronic pain, researchers discuss the advantages and implications of psychedelic treatments.
Trihexyphenidyl, an anticholinergic medication commonly prescribed for Parkinson's symptoms, appears to alleviate negative memory flashbacks and nightmares experienced by those with PTSD.
Osanetant, a drug that inhibits the Tac2 pathway, has opposite effects on the recall of traumatic events in male and female mice.
As interest in using psychedelics to treat a range of mental health disorders grows, researchers consider the impact and therapeutic benefits of using psychedelics to help alleviate symptoms of depression.
Fenofibrate, a drug developed to control cholesterol, alleviated brain and behavioral abnormalities in mouse models of schizophrenia.
Ezogabine, a drug that opens up the KCNQ2/3 type potassium channel, significantly improved symptoms of depression and anhedonia.
From microdosing to improve cognition, to treating a range of mental health disorders, researchers evaluate the rise in the use of psychedelics and their potential as medicines.
SSRI's, ketamine, and tricyclic antidepressants all bind with TrkB. The findings challenge the roles serotonin and glutamate receptors play in the effects of antidepressant medications.
4E-BPs proteins are key to unlocking ketamine's antidepressant effects. When 4E-BPs are absent in neurons, ketamine can not produce its antidepressant effect.
A new small scale study reveals the antidepressant fluvoxamine may be a new tool in the fight against COVID-19. Researchers report fluvoxamine reduced the severity of coronavirus symptoms and hospitalizations.
Degarelix, a drug that reduces testosterone levels, shows potential in the treatment of pedophilic disorder. Men with a history of child sexual abuse who took the drug had reduced overall sexual desire and decreased attraction toward children, with noticeable effects within two weeks.
Fish model study found a potential target for the treatment of seasonal affective disorder (SAD). Researchers implicated NRF2 in seasonal depression and reported celastrol may help in the treatment of SAD.
